The catecholamine release-inhibitory "catestatin" region of chromogranin A: Early decline in humans at genetic risk of hypertension

Annals of the New York Academy of Sciences

Volumn 971, Issue , 2002, Pages 533-535

  O'Connor, Daniel T ^a,c   Kailasam, Mala T ^a   Kennedy, Brian P ^a   Ziegler, Michael G ^a   Yanaihara, Noboru ^b   Parmer, Robert J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b Yanaihara Institute Inc   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Catecholamine; Catestatin; Chromaffin; Chromogranin; Ethnicity; Heredity; Hypertension; Leptin; Nicotinic cholinergic receptor

Indexed keywords

CATESTATIN; CHOLINERGIC RECEPTOR; CHROMOGRANIN A; LEPTIN; NICOTINIC RECEPTOR; STATIN; UNCLASSIFIED DRUG;

ADULT; AGED; AUTOCRINE EFFECT; BODY MASS; CATECHOLAMINE RELEASE; COLD STRESS; CONFERENCE PAPER; EXOCYTOSIS; FAMILY HISTORY; FEMALE; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEGATIVE FEEDBACK; PATHOPHYSIOLOGY;

EID: 0037024577     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04520.x     Document Type: Conference Paper

References (11)

1. Lander, E.S. & N.J. Schork. 1994. Genetic dissection of complex traits. Science 265(5181): 2037-2048.
2. Takiyyuddin, M.A. et al. 1990. Is physiologic sympathoadrenal catecholamine release exocytotic in humans? Circulation 81: 185-195.
3. Mahata, S.K. et al. 1997. Novel autocrine feedback control of catecholamine release: A discrete chromogranin A fragment is a non-competitive nicotinic cholinergic antagonist. J. Clin. Invest. 100: 1623-1633.
4. O'Connor, D.T. et al. 2000. Heredity and the autonomic nervous system in human hypertension. Curr. Hypertens. Rep. 2: 16-22.
5. Dao, T.T. et al. 1998. Expression of altered alpha-2-adrenergic phenotypic traits in normotensive humans at genetic risk of hereditary (essential) hypertension. J. Hypertens. 16: 779-792.
6. Goldstein, D.S. & I.J. Kopin. 1990. The autonomic nervous system and catecholamines in normal blood pressure control and in hypertension. In Hypertension: Pathophysiology, Diagnosis and Management, Chap. 7, J.H. Laragh and B.M Brenner, Eds. Raven Press. New York.
7. Ferrier, C., H. Cox & M. Esler. 1993. Elevated total norepinephrine spillover in normotensive members of hypertensive families. Clin. Sci. 84: 225-230.
8. Wu, R.A. et al. 1994. Does lipophilicity of angiotensin converting enzyme inhibitors selectively influence autonomic neural function in human hypertension? J. Hypertens. 12: 1243-1247.
9. Nishikawa, Y. et al. 1998. Region-specific radioimmunoassay for human chromogranin A. Biomed. Res. 19: 245-251.
10. Yanaihara, H. et al. 1999. Application of region-specific immunoassay for human chromogranin A: Substantial clue for detection and measurement of chromogranin A in human plasma. Regul. Pept. 80: 83-90.
11. Kailasam, M.T. et al. 1995. Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. Hypertension 26(1): 143-149.